FOLH1 and neoplasm: Less closely aligned with observations of most [2,14,19], but not all [16], of the four previously published studies and of the single case report [20] examining the issue in patients with higher tumor burdens, our findings suggest only a possible trend towards a tumor sink effect of PSMA-targeted radiopharmaceuticals in the liver.